Prescient Therapeutics (PTX) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Prescient Therapeutics embarks on board chair transition process as chair retiresMarch 11 at 1:36 AM | au.investing.comPrescient Therapeutics Reports Decreased Losses Amid Revenue DropFebruary 20, 2025 | tipranks.comPrescient Therapeutics Initiates Phase 2 Trial and Strengthens LeadershipJanuary 30, 2025 | tipranks.comPrescient Therapeutics resumes OmniCAR program after resolving technical challengesJanuary 23, 2025 | au.investing.comPrescient Therapeutics Overcomes OmniCAR Technical Challenges to Advance Cancer TreatmentJanuary 22, 2025 | tipranks.comPrescient Therapeutics Issues Unquoted Equity SecuritiesJanuary 21, 2025 | tipranks.comPrescient Therapeutics Reports Expiry of 1 Million OptionsJanuary 12, 2025 | tipranks.comPrescient Therapeutics Gains FDA Approval for PTX-100 TrialDecember 22, 2024 | tipranks.comPrescient Therapeutics Appoints New CEO for GrowthDecember 16, 2024 | tipranks.comPrescient Therapeutics Director Increases Stake in Future GrowthDecember 11, 2024 | tipranks.comPrescient Therapeutics Expands Cancer Treatment InnovationsDecember 4, 2024 | tipranks.comPrescient Therapeutics Warns of Investment RisksNovember 14, 2024 | markets.businessinsider.comPrescient Therapeutics Advances PTX-100 in Cancer TrialsOctober 31, 2024 | markets.businessinsider.comTrending On Livewire: Weekend Edition - Saturday 14th SeptemberSeptember 15, 2024 | msn.comPrescient Therapeutics CEO Yatomi-Clarke steps down; will remain available as a consultantSeptember 12, 2024 | au.investing.comPrescient Therapeutics Ltd PTXAugust 16, 2024 | morningstar.comPrescient ETF Adds New Securities to Its Income Provider Feeder FundMay 25, 2024 | msn.comPrescient Income Provider Feeder ETF Expands with New SecuritiesMay 22, 2024 | msn.comPrescient Expands Its Income Provider Feeder ETF PortfolioMay 20, 2024 | msn.comPrescient ETF Increases Securities with New ListingMay 18, 2024 | msn.comPrescient helps Reatile with equity injection to acquire a stake in Ursa EnergyMay 18, 2024 | msn.comPrescient Therapeutics Ltd (PTX)May 16, 2024 | investing.comPrescient Management Lists Additional PMXINC Securities on JSEMay 15, 2024 | msn.comPrescient Management Issues Over 114,000 New Securities in PMXINC ETFApril 26, 2024 | msn.comPrescient Management Expands Portfolio with Additional PMXINC Securities ListingApril 18, 2024 | msn.comPrescient Management Expands PIPETF Securities in the MarketApril 6, 2024 | msn.comPrescient ETF Expands Offering with Additional Securities ListingApril 4, 2024 | msn.comPrescient ETF Expands with New Listings in Global Property PortfolioMarch 26, 2024 | msn.comPrescient ETF Expands with New Securities ListingMarch 15, 2024 | msn.comWe're Hopeful That Prescient Therapeutics (ASX:PTX) Will Use Its Cash WiselyMarch 6, 2024 | finance.yahoo.comPrescient Therapeutics LimitedFebruary 1, 2024 | afr.comPrescient Therapeutics’ PTX-100 Phase 1b study shows excellent safety and promising efficacy in T-cell lymphoma patientsDecember 10, 2023 | au.investing.comMoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunityNovember 20, 2023 | msn.comPrescient Therapeutics nearing a potential payday with PTX-100: Pitt Street ResearchNovember 16, 2023 | proactiveinvestors.com.auPrescient Therapeutics to participate in prestigious conference; abstract online nowNovember 6, 2023 | au.investing.comCancer fighter Prescient navigates challenging conditions for biotech, reports strong Q1 FY24October 31, 2023 | msn.comPrescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conferenceOctober 17, 2023 | msn.comPrescient Therapeutics to present clinical data at prestigious US conferenceOctober 16, 2023 | proactiveinvestors.com.auASX cancer stocks guide: Here’s everything you need to knowSeptember 19, 2023 | msn.com‘Above and beyond approved therapies’: How Prescient Therapeutics is at the forefront of cancer fightingAugust 30, 2023 | msn.comPrescient Therapeutics showcases cell therapy data at prestigious ISCT conferenceJune 16, 2023 | finance.yahoo.comPrescient Therapeutics to present CellPryme and OmniCAR data to International Society of Cell and Gene TherapyMay 15, 2023 | proactiveinvestors.com.auPrescient Therapeutics bolsters board with appointment of experienced US-based pharma executiveMay 15, 2023 | proactiveinvestors.com.auPrescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth PlansApril 20, 2023 | finance.yahoo.comPrescient Therapeutics' PTX-100 T Cell Lymphoma Phase 1b trial continues to show promising resultsMarch 16, 2023 | proactiveinvestors.com.auASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good resultsMarch 15, 2023 | msn.comPrescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100March 9, 2023 | proactiveinvestors.com.auGuess which ASX biotech stock just rocketed 29% on big FDA newsMarch 8, 2023 | msn.comPrescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares upMarch 8, 2023 | proactiveinvestors.comHere's Why Shareholders Will Not Be Complaining About Prescient Therapeutics Limited's (ASX:PTX) CEO Pay PacketNovember 22, 2022 | finance.yahoo.com Remove Ads Get Prescient Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTX Media Mentions By Week PTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTX News Sentiment▼0.000.73▲Average Medical News Sentiment PTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTX Articles This Week▼10▲PTX Articles Average Week Remove Ads Get Prescient Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bioventix News 4basebio News Avacta Group News hVIVO News NervGen Pharma News Scancell News Oncolytics Biotech News Medicenna Therapeutics News Ondine Biomedical News Theratechnologies News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:PTX) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredElon’s desperate gambleWarning: "DOGE Collapse" Imminent After months of cost-cutting, controversy, and media buzz, DOGE is on the...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prescient Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Prescient Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
